Fate Therapeutics (FATE) EBITDA Margin Growth (5y) (2017 - 2026)
Powered by 
Analysis
Fate Therapeutics (FATE) EBITDA Margin Growth (5y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Fate Therapeutics | 299.79 Mn | 299.79 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -114,660.00 |
| Mar 31, 2026 | -212,568.00 |
| Dec 31, 2025 | -232,612.00 |
| Sep 30, 2025 | -157,851.00 |
| Jun 30, 2025 | -141,325.00 |
| Mar 31, 2025 | -116,262.00 |
| Dec 31, 2024 | -228,203.00 |
| Sep 30, 2024 | -58,740.00 |
| Jun 30, 2024 | 18,923.00 |
| Mar 31, 2024 | -187,606.00 |
| Dec 31, 2023 | -186,055.00 |
| Sep 30, 2023 | -101,091.00 |
| Jun 30, 2023 | -479,683.00 |
| Mar 31, 2023 | 132,131.00 |
| Dec 31, 2022 | 104,698.00 |
| Sep 30, 2022 | 43,113.00 |
| Jun 30, 2022 | 48,470.00 |
| Mar 31, 2022 | 56,648.00 |
| Dec 31, 2021 | 33,880.00 |
| Sep 30, 2021 | 43,365.00 |